BioCentury
ARTICLE | Clinical News

DNA IL-12: Preliminary Phase II data

November 5, 2012 8:00 AM UTC

Preliminary data from 5 evaluable patients in an open-label Phase II trial showed that ImmunoPulse was well tolerated and produced 1 confirmed partial response, defined as a >70% regression of both in...